Expediting Development of Novel ADCs Through WuXi XDC’s Innovative Technology Platform & Fully Integrated CMC Services
Time: 9:00 am
day: Conference Day One pt 1
Details:
• WuXiDAR4, our proprietary conjugation technology, produces more homogenous ADC compared to the DAR4 ADC generated through random conjugation. This results in enhanced efficacy, improved (PK), and a superior safety profile in clinical trials
• Sharing WuXi XDC’s novel linker and payload-linker, which enables the development of better ADCs with increased stability and a wider therapeutic index
• Showcasing our one-stop discovery service platform, which accelerates the selection of pre-clinical candidates, and our fully integrated CMC service, which reduce the ADC development timeline from DNA to IND filing to just 13-15 months
